All In Biotech

Drug Trial Radar · NCT04926571

Dexamethasone and COVID-19 Inpatient Mortality

Effect of Dexamethasone on Inpatient Mortality Among Hospitalized COVID-19 Patients

Last checked: Nov 20, 2026Latest source record: Apr 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14,105

Actual

Start

Apr 1, 2020

Primary completion

Aug 27, 2021

Study completion Aug 27, 2021

Sponsor

Lead sponsor
Aetion, Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 15, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to assess the effectiveness of dexamethasone initiation to reduce the risk of inpatient mortality within 28 days among US patients hospitalized with COVID-19 diagnosis or SARS-CoV-2 infection, overall and stratified by COVID-19 severity subgroups.

Conditions

  • Coronavirus

Interventions

  • Dexamethasone OralDrug

    New users of Dexamethasone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MortalityTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aetion, Inc.

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.